Oliver Stoeltzing, MD

home / authors / oliver-stoeltzing-md

Articles

Synopsis of Angiogenesis Inhibitors in Oncology

Lee M. Ellis, MD, FACS;Wenbiao Liu, MD;Fan Fan, MD;Young Do Jung, MD, PhD;Niels Reinmuth, MD;Oliver Stoeltzing, MD;Akihiko Takeda, MD;Morihisa Akagi, MD;Alexander A. Parikh, MD;Syed Ahmad, MD

May 1st 2002

Angiogenesis is a dynamic process essential for primary tumor growth and metastases. New insights into the basic understanding of the biologic processes responsible for angiogenesis have led to the characterization of potential therapeutic targets. Several strategies for the development of antiangiogenic therapeutic modalities have been employed, including agents that (1) decrease the activity of specific angiogenic factors, (2) decrease the activity of endothelial survival factors, (3) increase the activity of naturally occurring antiangiogenic agents, or (4) indirectly downregulate angiogenic and survival factor activity.